Key result
Clopidogrel may be less effective in reducing mortality and preventing ischemic events in hemodialysis patients, prompting the need to explore alternative P2Y12 receptor inhibitors.
This review discusses the pharmacokinetic and pharmacodynamic reasons why clopidogrel may be less effective in hemodialysis patients and explores the risks and benefits of alternative P2Y12 inhibitors.
May warrant caution with clopidogrel in hemodialysis; leaves open whether alternatives improve outcomes.
Oral P2Y12 receptor inhibitors are commonly used drugs in patients on hemodialysis (HD) to treat acute coronary syndrome with or without percutaneous coronary intervention (PCI), and patients with stable coronary artery disease after PCI. Clopidogrel is the most commonly prescribed P2Y12 receptor inhibitor because it is effective in the general population and is not as costly as newer FDA-approved agents (prasugrel, ticagrelor). However, increasing evidence is accumulating that clopidogrel may not be as effective in reducing mortality and preventing future ischemic events in patients with kidney disease. In this review, we will explore some of the studies that form the basis for this statement and discuss potential pharmacokinetic and pharmacodynamic reasons why clopidogrel might be less effective in HD patients, as well as explore potential risks and benefits of alternatives to clopidogrel therapy.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2016) conducted a review in Hemodialysis patients undergoing percutaneous coronary intervention or with acute coronary syndrome. Oral P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) was evaluated. Clopidogrel may be less effective in reducing mortality and preventing ischemic events in hemodialysis patients, prompting the need to explore alternative P2Y12 receptor inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: